Effect of Extracorporeal Shockwave Therapy on Pruritus in Neurodermatitis Patients
NCT ID: NCT07206680
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
34 participants
INTERVENTIONAL
2024-12-15
2025-10-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Although new modalities are continuously coming up for pruritus, there remains a great gap for providing symptom relief.
Furthermore, there is a lack in the quantitative knowledge and information in the published studies about benefits of shockwave therapy on the treatment of pruritus in neurodermatitis patients. So, this study is designed to outline the therapeutic efficacy of shockwave therapy on the treatment of pruritus in neurodermatitis patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Shockwave therapy + corticosteroids + emollients
It will include 17 patients suffering from neurodermatitis who will receive shockwave therapy for 10min, 4 sessions, once per week and emollients \& corticosteroids for a month.
Shockwave therapy
The procedures for Extracorporeal Shockwave Therapy (ESWT) involve several steps. First, the patient is positioned comfortably, and the physiotherapist explains the treatment procedure. Before the session begins, the device cables are checked for proper functioning. The shockwave type used is Non-Focused/Radial, with a treatment duration not exceeding 10 minutes. The frequency is set at 4 Hz, and the intensity ranges from 0.05 to 0.20 mJ/mm². Each session involves a total of 1000 to 2000 shocks. The treatment consists of four sessions, each held once a week.
Emollients & corticosteroids
Patients in both groups will receive emollients \& corticosteroids for one month.
Corticosteroids & Emollients
It will include 17 patients suffering from neurodermatitis who will receive their emollients \& corticosteroids only for a month.
Emollients & corticosteroids
Patients in both groups will receive emollients \& corticosteroids for one month.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Shockwave therapy
The procedures for Extracorporeal Shockwave Therapy (ESWT) involve several steps. First, the patient is positioned comfortably, and the physiotherapist explains the treatment procedure. Before the session begins, the device cables are checked for proper functioning. The shockwave type used is Non-Focused/Radial, with a treatment duration not exceeding 10 minutes. The frequency is set at 4 Hz, and the intensity ranges from 0.05 to 0.20 mJ/mm². Each session involves a total of 1000 to 2000 shocks. The treatment consists of four sessions, each held once a week.
Emollients & corticosteroids
Patients in both groups will receive emollients \& corticosteroids for one month.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female patients will participate in the study.
* All patients have neurodermatitis.
* All patients will be received the same approach of medication and nursing care.
* All patients enrolled in the study will have their informed consent.
Exclusion Criteria
* Pregnant woman.
* active infection.
* Patients with any systemic diseases that may interfere with the objectives of the study.
* Cardiac pacemakers or other implantable devices.
* Current anticoagulation use.
* Any other cause of itching
55 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abd Al Rahman Khaled Muhammed Muhammed
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nessrien Afify Abd El Rashid, PhD
Role: STUDY_CHAIR
Assistant Professor, Cairo University
Noha Zakaria Tawfik, PhD
Role: STUDY_DIRECTOR
Assistant Professor, Suez Canal University
Doaa Atef Aly, PhD
Role: STUDY_DIRECTOR
Lecturer, Cairo university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Suez Canal University Hospital
Ismailia, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P.T.REC/012/005978
Identifier Type: -
Identifier Source: org_study_id